Al frente de GSK se encuentra la primera mujer que dirige una de las Big Pharma Emma Walmsley, un subalterno suyo Hal Barron -presidente de desarrollo e investigación de GSK desde marzo de 2018 - ha hecho una presentación de la I+D de la empresa: A new approach to R&D at GSK. En el powerpont en la diapo 4 se mencionan los productos que tienen en las diversas fases hasta llegar al mercado. Para 2018-2020:
Y lo que preven se autorice en 2021-2026:
‘091 (TLR4) Advanced Solid Tumors
‘165 (aGM-CSF) rheumatoid arthritis (RA)
’254 (HIV MI) AIDS
‘404/’836 (HBV) Hepatitis
‘557 (PI3Kδ) COPD
‘595 (PRMT5 inhibitor) solid tumor and mantle cell lymphoma (MCL)
‘609 (ICOS) solid tumours.
‘656 (leucyl tRNA) M. tuberculosis Leucyl-tRNA Synthetase Inhibitor
‘672 (IBAT) ileal sodium-dependent bile acid transporter inhibitor,
‘745 (TRPV4) Congestive Heart Failure
‘756 (CXCR2) " inflammation, such as pulmonary diseases.
‘762 (BET inhibitor) human cancer
‘794 (NY ESO-1) solid tumours
‘847 (IL33R) Severe astma
‘863 (HIF-PHI) anemia
‘944 (topoisomerase IV inhibitor) antibacterial
‘998 (OX40) cancer
CAB PrEP (HIV)
Benlysta+ rituximab (SLE)
Comparando las indicaciones de los dos bloques se ve el tránsito de VIH a Inmuno-Oncología.
En dicho documento presentan su estrategia de futuro basada en tres apoyos: Ciencia, Tecnología y Cultura.
En la presentación de resultados del Q2 de 2018 se presenta en formato texto, la misma estrategia:
Science
Going forward, GSK’s Research will have an even greater focus on the basic biology of the immune system as well as targets that have a high degree of validation based on human genetics. Medicines targeting mechanisms of action with strong human genetic validation have a higher (2-fold) probability of success. This means a shift to a genetics-driven (vs genetics-supported) portfolio.
GSK’s Pharmaceutical and Vaccines businesses have a deep history of developing novel and competitive assets targeting the immune system. The company currently has 27 immunomodulatory NMEs (new molecular entities) in the clinic, representing 60% of the total clinical pipeline. Of these 27 assets, more than half are potential first-in-class therapy options for a range of different diseases. In Oncology, GSK is developing a number of assets using different immune-based approaches: cell therapy, epigenetic modulators and antibodies targeting immune cells (agonists and antagonists).
Access to databases that can be used to assess the impact of genetic variation on human disease offers significant opportunities to improve drug development. Today GSK announced a major advance in this capability with the formation of a new collaboration with 23andMe, the world’s leading consumer genetics and research company. This collaboration offers GSK a transformational opportunity to utilise 23andMe's database and statistical analytics to identify disease-relevant genes and novel targets. 23andMe currently has 5 million customers and growing, making it the world’s largest genetic and phenotypic resource. GSK will also be able to benefit from 23andMe’s ability to identify patients with specific gene variations in specific diseases, helping significantly accelerate recruitment for new clinical studies. This new collaboration complements GSK’s existing investments in the EBI/Sanger Open Targets consortium, Altius Institute, and the UK Biobank.
Technology
Investing in advanced technology platforms, such as machine learning, to support interpretation of genetics data will be an important part of enabling the new R&D approach. In addition, the Group will be investing in functional genomics to validate potential targets, applying techniques for gene modification such as CRISPR technology. GSK will also invest in computational design, automation and new capabilities to assess the indication potential, selection, sequencing and management of evidence generation for new assets over the lifecycle. These investments will supplement GSK’s existing strengths in other technologies, including a leading position in Cell and Gene Therapy.
No obstante, están buscando Global Marketing Director - Oncology (BCMA) coherentemente con el plan de "as we prepare for GSK’s re-entry into the Global Oncology market."
Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios.
| Shingrix (vacuna herpes zoster) |
| Trelegy (triple principio para EPOC) |
| Juluca (AIDS) |
| Tafenoquine (MALARIA) |
| Nucala (ASMA) |
| DTG+3TC (AIDS) |
| CAB+RPV (AIDS) |
| Trelegy (asthma) |
| ‘916 (BCMA) (Mieloma Multiple) |
| fostemsavir (AIDS) |
Y lo que preven se autorice en 2021-2026:
‘091 (TLR4) Advanced Solid Tumors
‘165 (aGM-CSF) rheumatoid arthritis (RA)
’254 (HIV MI) AIDS
‘404/’836 (HBV) Hepatitis
‘557 (PI3Kδ) COPD
‘595 (PRMT5 inhibitor) solid tumor and mantle cell lymphoma (MCL)
‘609 (ICOS) solid tumours.
‘656 (leucyl tRNA) M. tuberculosis Leucyl-tRNA Synthetase Inhibitor
‘672 (IBAT) ileal sodium-dependent bile acid transporter inhibitor,
‘745 (TRPV4) Congestive Heart Failure
‘756 (CXCR2) " inflammation, such as pulmonary diseases.
‘762 (BET inhibitor) human cancer
‘794 (NY ESO-1) solid tumours
‘847 (IL33R) Severe astma
‘863 (HIF-PHI) anemia
‘944 (topoisomerase IV inhibitor) antibacterial
‘998 (OX40) cancer
CAB PrEP (HIV)
Benlysta+ rituximab (SLE)
Comparando las indicaciones de los dos bloques se ve el tránsito de VIH a Inmuno-Oncología.
En dicho documento presentan su estrategia de futuro basada en tres apoyos: Ciencia, Tecnología y Cultura.
En la presentación de resultados del Q2 de 2018 se presenta en formato texto, la misma estrategia:
Science
Going forward, GSK’s Research will have an even greater focus on the basic biology of the immune system as well as targets that have a high degree of validation based on human genetics. Medicines targeting mechanisms of action with strong human genetic validation have a higher (2-fold) probability of success. This means a shift to a genetics-driven (vs genetics-supported) portfolio.
GSK’s Pharmaceutical and Vaccines businesses have a deep history of developing novel and competitive assets targeting the immune system. The company currently has 27 immunomodulatory NMEs (new molecular entities) in the clinic, representing 60% of the total clinical pipeline. Of these 27 assets, more than half are potential first-in-class therapy options for a range of different diseases. In Oncology, GSK is developing a number of assets using different immune-based approaches: cell therapy, epigenetic modulators and antibodies targeting immune cells (agonists and antagonists).
Access to databases that can be used to assess the impact of genetic variation on human disease offers significant opportunities to improve drug development. Today GSK announced a major advance in this capability with the formation of a new collaboration with 23andMe, the world’s leading consumer genetics and research company. This collaboration offers GSK a transformational opportunity to utilise 23andMe's database and statistical analytics to identify disease-relevant genes and novel targets. 23andMe currently has 5 million customers and growing, making it the world’s largest genetic and phenotypic resource. GSK will also be able to benefit from 23andMe’s ability to identify patients with specific gene variations in specific diseases, helping significantly accelerate recruitment for new clinical studies. This new collaboration complements GSK’s existing investments in the EBI/Sanger Open Targets consortium, Altius Institute, and the UK Biobank.
Technology
Investing in advanced technology platforms, such as machine learning, to support interpretation of genetics data will be an important part of enabling the new R&D approach. In addition, the Group will be investing in functional genomics to validate potential targets, applying techniques for gene modification such as CRISPR technology. GSK will also invest in computational design, automation and new capabilities to assess the indication potential, selection, sequencing and management of evidence generation for new assets over the lifecycle. These investments will supplement GSK’s existing strengths in other technologies, including a leading position in Cell and Gene Therapy.
Así pues ante un futuro potente actor en inmuno-oncología, aunque en ATM, si bien ya están presentes a través del 15% de Orchard que mantienen, en Strimvelis, no tienen mas que un producto de terapia celular. (NY-ESO-1) un TCR-T-
No obstante, están buscando Global Marketing Director - Oncology (BCMA) coherentemente con el plan de "as we prepare for GSK’s re-entry into the Global Oncology market."
Le ruego evalúe la presente entrada asignando un valor de 1 a 5, de peor a mejor valorada, usando la opción de comentarios.
Comentarios
Publicar un comentario